Rx - AMCo

Report
AMCo – new beginnings
20th November 2013
Presenter
John Beighton
•
Medical Rep/Regional Manager - Smith Kline and French UK
–
•
Various sales and marketing jobs – SmithKline Beecham UK
–
•
2002-2009
VP Global Business Optimisation – Teva Pharmaceutical Ind.
–
•
1997-2002
Managing Director Teva UK
–
•
1990-1997
Commercial Director – APS Berk/Teva UK
–
•
1981-1990
2009 – 2010
CEO AMCo
–
2010 to date
Company Origins
“G word”
Mar-12
Oct-12
Aug-12
£367m
£465m
Jan-13
Refinancing
Rebranding
Revenues in the United Kingdom
38
Countries with commercial presence
Rx
------
------
------
80%
------
million
2012 Sales
------
------
------
£106
------
Established 1991, Headquarters in South London
Acquired by Cinven (Private Equity) August 2012 for £465 million
------
------
1991
Established Brands and Generics
Virtual Business Model (R&D, Manufacturing outsourced)
Mercury Pharma
------
2002
------
Established 2002, Headquarters East of London.
Acquired by Cinven (Private Equity) August 2012 for £367 million
------
£109
million
------
2012 Sales
------
34%
------
Revenues in the United Kingdom
------
100+
------
Countries with commercial presence
------
Rx
------
Established Brands and Generics
Virtual Business Model (R&D, Manufacturing outsourced)
Amdipharm
million
60%
112
Rx
------ ------ ------ ------ ------
------ ------ ------ ------ ------
£248
------
------
2013
Combined group rebranded AMCo in March 2013
UK Office to be relocated to Central London
2013 Expected revenues (15% Growth)
Revenues in the United Kingdom
Countries with commercial presence
Established Brands and Generics
Virtual Business Model (R&D, Manufacturing outsourced)
Amdipharm Mercury (AMCo)
Acquisition History
Eltroxin
levothyroxine
£27m
13 Countries
Liothyronine
Diamox
Hytrin
Hygroton
Ludiomil
Cafergot
liothyronine
£10m
10 Countries
acetazolamide
£5m
27 Countries
terazosin
£5m
21 Countries
chlortalidone
£5m
12 Countries
maprotiline
£3m
25 Countries
ergotamine
£2m
26 Countries
1992
2001
1999
Macrodantin, Furadantin,
Macrobid, Furabid
nitrofurantoin
£18m
18 Countries
figures quoted are 2013 forecast revenues
2006
2004
2008
2007
2013
Neomercazole
Erythrocin
Akineton
Transact
Fucithalmic
carbimazole
£12m
20 Countries
erythromicin
£16m
32 Countries
biperiden
£7m
21 Countries
flurbiprofen
£8m
2 Countries
fusidic acid
£26m
>90 Countries
Management Team
John Beighton
CEO
Peter van Tiggelen
CFO
Robert Sully
General
Counsel
Bharat Karbal
Medical &
Regulatory
Brian McEwan
Managing Director
Amdipharm
Guy Clark
Strategic
Development
John Cowell
Human
Resources
Vikram Kamath
Finance Director
Simon Tucker
International
Commercial
Karl Belk
Global
Operations
Jane Hill
UK
Commercial
Company Performance
Sales History by Company
2010
£79
£125
2010 to 2013 est.
2011
£88
2012
£113
£106
2013
£109
£126
£0
£50
£122
£100
Mercury
£150
Amdipharm
£200
£250
Millions
Top 10 Molecules (Percentage of 2012 revenue)
Levothyroxine
11%
Erythromicin
8%
Nitrofurantoin
7%
Flurbiprofen
5%
Codeine +
paracetamol
5%
Biperiden
4%
Liothyronine
4%
Carbimazole
4%
Prednisolone
4%
Cyclizine
3%
AMCo Strategy
• Consolidate strong position in UK
– Off-patent brands and niche products
UK Commercial Team
Jane Hill
UK Commercial
Director
Jeremy Devaney
Hospitals
Jenna Pritchard
National Accounts
Neil Cook
Promoted Products
AMCo Strategy
• Focus on 5 Business Action Plans
– Operational Excellence
– Culture and Integration
– Compliance – Quality and Reputation
– International Excellence
– Strategic Growth
Global Coverage
>50% of sales in UK
AMCo offices/direct presence
Distributor network
International Excellence
AMCo offices/direct presence
Distributor network
Target markets – direct presence
Strategic Growth
Licensing
Development
Acquisition
Dedicated business development team focused
on driving revenue and profit growth
Brands
Primary & Secondary Care
•Low Competition
•Stable Revenues and Profit
•Multiple Markets
•Growth Opportunities
Therapeutic Focus
Primary & Secondary Care
•Ophthalmology
•Endocrinology
•Urology
•Infectious Diseases
•Pain & Anaesthesia
Geographic Expansion
Generics
Companies & Products
Primary & Secondary Care
•Company acquisitions
•Build out in Target Markets
•Portfolio Optimisation
•Distributor consolidation
•Low Competition
•Barriers to Entry
•Branded Generics
•Sustainable Pricing
Strategic Development Activity
•
Portfolio Optimisation – registering existing AMCo products into new markets where the
product isn’t currently registered or sold, and using the existing manufacturers to make the
product
•
Product Development – creating new products with a contract development partner,
whereby AMCo retains full ownership rights to the product, and freedom to choose who to
manufacture the product
•
In-Licensing – buying the rights to sell a third party’s product in a defined territory, and
agreeing for the licensor to supply the product to AMCo for an agreed period of time
(typically 5 years)
•
Product Acquisitions – buying the permanent rights to own an existing product, in a
defined territory (sometimes global e.g. Fucithalmic). The seller may wish to continue making
the product, but more often would require AMCo to find a new supplier within 2-3 years
United Kingdom
Ireland
India
No. 1 Croydon
12-16 Addiscombe Road
Croydon CR0 0XT
102 Block B
The Crescent Building
Northwood
Santry
Dublin 9
101 Vedanta
779 Makwana Road
Marol
Andheri East
Mumbai 400 059
+353 (0)1 6971640
+91 22 6678 4444
+44 (0)20 8649 8500
www.amcolimited.com
Committed to being a socially responsible company, we support:

similar documents